Given the recent findings of the ATG7′s oncogenic effect on promoting BC progression, our new results provide the potential for developing a combination treatment with autophagy inhibitors and PD-1/PD-L1 immune checkpoint blockade therapeutic strategy for human BC patient treatment. This evidence concerns the gene ATG7 and breast cancer.